Cargando…
Comparison of the Treatment Outcome of Piperacillin-Tazobactam versus Carbapenems for Patients with Bacteremia Caused by Extended-Spectrum β-Lactamase-Producing Escherichia coli in Areas with Low Frequency of Coproduction of OXA-1: a Preliminary Analysis
Although piperacillin-tazobactam (TZP) was shown to be less effective than carbapenems in treating bacteremia due to extended-spectrum β-lactamase-producing (ESBL)-producing organisms in a randomized controlled trial, the fact that many of the causative organisms co-produced inhibitor-resistant OXA-...
Autores principales: | Hoashi, Kosuke, Hayama, Brian, Suzuki, Masahiro, Sakurai, Aki, Takehana, Kazumi, Enokida, Taisuke, Takeda, Koichi, Ohkushi, Daisuke, Doi, Yohei, Harada, Sohei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430612/ https://www.ncbi.nlm.nih.gov/pubmed/35916524 http://dx.doi.org/10.1128/spectrum.02206-22 |
Ejemplares similares
-
2442. Outcomes in ESBL Bacteremia Empirically Treated With Piperacillin/Tazobactam or Carbapenems
por: John, Reeba, et al.
Publicado: (2018) -
Clinical characteristics of peripheral venous catheter-associated gram-negative bloodstream infection among patients with malignancy
por: Sasaki, Toshiharu, et al.
Publicado: (2020) -
Piperacillin–tazobactam as alternative to carbapenems for ICU patients
por: Pilmis, Benoit, et al.
Publicado: (2017) -
Clinical characteristics and risk factors associated with Pneumocystis jirovecii infection in patients with solid tumors: study of thirteen-year medical records of a large cancer center
por: Takeda, Koichi, et al.
Publicado: (2021) -
Carbapenem vs. Piperacillin-tazobactam for the Treatment of Ceftriaxone-Resistant Gram-Negative Bacteremia: Matched Cohorts by Propensity Score
por: Rajagopal, Sumanth, et al.
Publicado: (2017)